source
- FDA approves small-molecule dasatinib formulation, expanding CML treatment optionsDr Michael J. Mauro explained that the FDA gave its nod in November 2025 to a generic, small-molecule version of dasatinib, the drug sold as Sprycel, for adult patients with Philadelphia-positive c…
- EnGene shares tumble 80% after Phase 2 bladder cancer data raise safety concernsEnGene, a Canadian biotech firm, released updated Phase 2 results for its experimental therapy aimed at a specific group of bladder cancer patients. The company said the new data fell short of expe…